



ENABLING ENVIRONMENTAL & SOCIETAL BENEFITS

VICTREX PLC
PRELIMINARY RESULTS
5 DECEMBER 2023



BRINGING TRANSFORMATIONAL & SUSTAINABLE SOLUTIONS THAT ADDRESS WORLD MATERIAL CHALLENGES EVERY DAY

INTRODUCTIONS



Jakob Sigurdsson
Chief Executive Officer



Ian Melling
Chief Financial Officer



KEY MESSAGES

**PBT
IN-LINE***

**WELL-PLACED
FOR RECOVERY**

**CONFIDENCE
IN DELIVERY**

1. Strong ASPs
2. Cost discipline
3. Targeted investment

1. Macro drivers
2. Differentiated products
3. Well invested assets

1. Core growth
2. Cashflow improvement
3. Mega-programmes

*with revised guidance of June 2023

FY 2023 SUMMARY

ROBUST CORE BUSINESS

- Macro & end market weakness
- Record Medical revenues
- Strong ASPs
- Adjusted PBT in-line at £80.0m

MEGA-PROGRAMME PRIORITISATION

- Key milestones delivered
- E-mobility ahead of expectations
- Prioritise investment (5 programmes)
- Inflection points approaching

STRONG BALANCE SHEET

- Well invested assets & new capacity
- Available cash £30.1m¹ (post major capex)
- China manufacturing ready
- Short/mid-term cashflow improvement


¹ Alternative performance measures are defined in the Appendix on slide 38

**PBT IN-LINE WITH EXPECTATIONS:
WELL-PLACED FOR MACRO & END-MARKET RECOVERY**

FINANCIAL UPDATE



Ian Melling
Chief Financial Officer



INCOME STATEMENT

PBT IN-LINE* AFTER CHALLENGING YEAR

- FY 2023 revenue down 10%
 - End market weakness in Sustainable Solutions
 - Record performance in Medical
- Underlying PBT in-line at £80.0m
- Reported PBT £72.5m (exceptional items of £7.5m driven by ERP investment)
- Total dividends maintained at 59.56p (flat)

¹ Alternative performance measures are defined in the Appendix on slide 38
 *in-line with revised guidance of 14 June 2023

Year ended 30 September

	2023	2022	Change	Change (constant currency) ¹
	£m	£m	%	%
Revenue	307.0	341.0	-10%	-13%
Losses on foreign currency net hedging*	(7.6)	(2.8)	171%	
Gross profit	162.6	174.5	-7%	-10%
<i>Gross margin %</i>	53.0%	51.2%	+180bps	
<i>FX hedge-adjusted gross margin %¹</i>	54.3%	51.6%	+270bps	
Operating overheads**	(81.9)	(78.1)	5%	1%
Interest	0.6	0.2		
Share of loss of associate	(1.3)	(1.0)		
Underlying profit before tax¹	80.0	95.6	-16%	-18%
Exceptionals	(7.5)	(7.9)		
Profit before tax	72.5	87.7	-17%	-19%
Underlying earnings per share (pence)¹	77.7	95.0	-18%	NA
Earnings per share (pence)	70.9	87.6	-19%	NA
Dividend per share	59.56p	59.56p	0%	NA


* Losses on foreign currency contracts, when net hedging is applied on cash flow hedges, are disclosed separately within gross margin on adoption of IFRS 9.

** Excluding exceptional items of £7.5m (FY22: charge of £7.9m)

PBT IN-LINE WITH GUIDANCE AND CONSENSUS

UNDERLYING PBT BRIDGE

FY 2023 v FY 2022




WEAKER VOLUMES OFFSETTING PRICE, MIX & FX

ASP & MARGIN

£/kg Average selling price (ASP)

Gross margin (GM) %



ASP UP 18% TO £85/KG

- FY 2023 ASP £85.3/kg (FY 2022 £72.1/kg)
- FY 2023 ASP in CC £83.2/kg
- Benefiting from structural price increases, mix & FX

GROSS MARGIN UP 180 BPS TO 53.0%


- FY 2023 Gross margin 53.0%, driven by price, mix & FX (offset by short-term impact of lower asset utilisation)
- FX hedge adjusted GM¹ 54.3% (FY 2022: 51.6%)

¹ Alternative performance measures are defined in the Appendix on slide 38

STRONG AVERAGE SELLING PRICES & IMPROVED GROSS MARGIN

GROSS MARGIN BRIDGE


FY 2023 v
FY 2022



INFLUENCE ON GROSS MARGIN %	FY 2024	MID-TERM (VS FY 2024)
China start-up & ramp-up	↓	↑
Input costs	↑	↑
Volume leverage/ asset utilisation	↓	↑
Sales mix (Sustainable Solutions/Medical)	↓	↑
Decarbonisation costs	-	↓

**GROSS MARGIN IMPROVEMENT DRIVEN BY PRICE, MIX & FX:
RETAIN MID-TERM GOAL OF MID-HIGH 50s GROSS MARGIN**

INVENTORY



INVENTORY REFLECTS LOWER ASSET UTILISATION (UK ASSET IMPROVEMENT SHUTDOWN), ENERGY & RAW MATERIAL COSTS & WEAKER MACRO ENVIRONMENT

FUTURE DRIVERS ON INVENTORY

- *Trading environment*
- *Asset shutdowns*
- *Safety stock levels*
- *Energy & raw material costs*
- *Unwind through FY 2024/25 (closer to £100m)*
 - *Broader asset & customer portfolio = strategically higher inventory vs history*

CURRENCY

Spot rates adverse for FY 2024, before favourable impact of hedging

	2022			2023		Change	
	Reported £m	Before impact of hedging £m	Currency Spot Impact £m	Constant currency ¹ £m	As reported £m	Before impact of hedging £m	Constant currency ¹ £m
Revenue	341.0	341.0	10.5	351.5	307.0	307.0	-13%
Gain/(loss) on foreign currency net hedging	(2.8)	-	-	-	(7.6)	-	
Gross profit	174.5	177.3	11.3	188.6	162.6	170.2	-10%
Gross margin %	51.2%	52.0%		53.7%	53.0%	55.4%	
Profit before tax	87.7	90.5	8.1	98.6	72.5	80.1	-19%
Revenue net of impact of hedging gain/(loss)	338.2				299.4		
FX hedge-adjusted gross margin % ¹	51.6%				54.3%		

Exchange rates

		2022	2023	2024	Exchange rate sensitivity ⁴
Year end rate	\$/£	1.10	1.22	-	
	€/£	1.13	1.16	-	
Effective rates ² :	\$/£	1.38	1.30	1.24	£2.7m
	€/£	1.14	1.17	1.13	£4.2m
Weighted average spot rates ³ :	\$/£	1.30	1.16	1.27	
	€/£	1.16	1.14	1.16	

¹ Alternative performance measures are defined in the Appendix on slide 38

² Effective rates (includes the impact of hedging)

³ Weighted average spot exchange rates (before the impact of hedging), 2024 spot rates at 1 December 2023

⁴ Management estimate of impact on 2024 full year forecast PBT from a 5% movement in weighted average spot exchange rates (before the impact of hedging)

CURRENCY TAILWIND IN FY 2023: £3m at PBT

CASH

Cashflow reflects capex & higher inventory

	FY2023 £m	FY2022 £m
Operating profit before exceptionals	80.7	96.4
Depreciation, amortisation and loss on disposal	21.6	24.0
EBITDA	102.3	120.4
Change in working capital	(48.9)	(27.5)
Capital expenditure	(38.5)	(45.5)
Operating cash flow	14.9	47.4
Operating cash conversion	18%	49%
Interest received	1.0	0.3
Interest paid	(0.2)	(0.4)
Net income tax paid	(2.0)	(10.6)
Exceptional cost	(7.5)	(7.9)
Other	(3.0)	5.7
Free cash flow	3.2	34.5
Investments	-	4.2
Loan to associated undertaking	(2.9)	(2.3)
Dividends	(51.8)	(95.2)
Cash received from NCI *	2.6	-
Net movement in bank borrowings **	17.2	14.5
Other	(2.6)	(1.7)
Net cash flow	(34.3)	(46.0)
Exchange differences	(1.0)	2.4
Net cash at 1st October	68.8	112.4
Net cash at 30th September	33.5	68.8
Other financial assets ***	0.1	10.1
Cash and cash equivalents	33.4	58.7
	33.5	68.8

* Comprising equity investment of £0.9m and loan of £1.7m

** Net movement in bank borrowings relates to an overseas bank loan which is funding capital expenditure in China

*** Other financial assets relates to cash held in 95-day deposit accounts

CASH SUPPORTS INVESTMENT & SHAREHOLDER RETURNS

- Net cash £33.5m (FY 2022: £68.8m)
- Available cash £30.1m (FY 2022: £66.0m) (adjusted for cash ring-fenced in China subsidiaries)
- Maintained final dividend of 46.14p/share

WORKING CAPITAL SUMMARY


- Working capital movement £48.9m

¹ Alternative performance measures are defined in the Appendix on slide 38

CAPITAL EXPENDITURE:

MAJOR INVESTMENT PHASE CONCLUDING

RECENT INVESTMENTS



NEW CAPACITY & CAPABILITY

- UK Asset Improvement (+1k tonnes, £15m total capex, completing H1 24)
- UK capacity now >8k tonnes
- China 1st PEEK & ready for ramp-up

CAPEX MODERATING

- Capex reducing to 8-10% of sales
- FY 2024 capex ~£30m-£35m
- ESG/decarbonisation capex in plan

CHINA:

1st VICTREX™ PEEK PRODUCED AHEAD OF COMMERCIAL START-UP

- Commissioning concluding: ramp-up in 2024
- Type 2 PEEK: portfolio extension
- Additional capability with compounding
- Nameplate capacity of 1,500 tonnes



LOOKING TO THE FUTURE: BENEFITING FROM A MACRO & END-MARKET RECOVERY

COGS



PRODUCTIVITY &
OPERATING LEVERAGE

- Energy costs reducing but volatile
- Raw material costs now deflationary
- China ramp-up
- Focus on improving asset utilisation (polymer & downstream assets)


OPERATING COSTS



COST DISCIPLINE & TARGETED
INNOVATION SPEND

- More modest future investment (targeting low single-digit % increase, incl salary/reward)
- Strong R&D investment, c5-6% of sales
- Increased digitalisation supporting customers
- Further enhance commercial delivery

CASHFLOW




DRIVE IMPROVED CASHFLOWS:
SUPPORT INVESTMENT & RETURNS

- Inventory unwind over ~2 years
- Lower mid-term capex requirements – capacity in place for broader portfolio
- Retain M&A options (capability/adjacencies)
- Optionality for shareholder returns (special dividends & buybacks; grow regular dividend when cover at ~2x)

PERFORMANCE UPDATE



Jakob Sigurdsson
Chief Executive Officer



SUSTAINABLE SOLUTIONS UPDATE



AUTOMOTIVE: STABLE PERFORMANCE, STRONG PROGRESS IN EV

- *FY 2023 Automotive volumes flat (revenue +9%), industry recovering*
- *Strong E-mobility business, £6m revenue & new customer wins*
- *Good growth in PEEK Gears (eg E-bikes), revenue £6m*



AEROSPACE: STRONG GROWTH & NEW APPLICATIONS

- *FY 2023 Aerospace volumes +20%; application growth & plane build*
- *AE™250 composite tape & new COMAC (China) volumes*



ENERGY & INDUSTRIAL: CYCLICAL DOWNTURN & LOWER CAPEX

- *FY 2023 Energy & Industrial volumes -23% (Energy -19%)*
- *Deferred capital equipment & destocking; new business wins in Renewables*



ELECTRONICS: CHALLENGING END MARKET

- *FY 2023 Electronics -23%, driven by Semicon & smart device downturn*
- *Favourable market indicators for 2024; broader application opportunities*

VALUE ADDED RESELLERS (VAR): DESTOCKING & MACRO IMPACT

- *FY 2023 volumes -39% (vs record FY 2022)*


TRANSPORT PROGRESS; MACRO WEAKNESS IN SEVERAL END MARKETS

MEGA-PROGRAMME UPDATE: E-MOBILITY

COMMERCIALISATION AHEAD OF EXPECTATIONS

- Strong progress: £6m revenues in FY 2023
- VICTREX XPI™ polymer – focused on wire coating and related applications, 800V next generation batteries
- Global pipeline & strong focus in China
- Potential content in an EV >200g of PEEK*

*based on an 800V electric vehicle (current PEEK content average in ICE & hybrid vehicles c10g)



Multiple applications
in E-mobility



Strategic collaboration
(Well Ascent, major global
EV wire coater – supplying
into major car brands)



MEGA-PROGRAMME UPDATE: MAGMA

INDUSTRIALISATION AND SCALE-UP PROGRESSING IN BRAZIL

- Hybrid Flexible Pipe (HFP) based on Victrex PEEK, Victrex composite tape & Victrex pipe extrusion IP
- Multiple field & multi-year opportunity
- 50% lighter vs conventional flexibles; reduced carbon footprint

"Hybrid Flexible Pipe provides an innovative customer solution, with significant market opportunities in Brazil and other countries"

TechnipFMC


1km of pipe (6 inch) offers potential for 8 tonnes of PEEK

MEDICAL UPDATE

RECORD PERFORMANCE & A BROADER PORTFOLIO

- Record revenues of £65.2m, +12%
- Growth across all regions (including FX):
(Asia +31%, Europe +9%, US +4%)
- Core business & new segment growth
(Spine +3%, Arthroscopy +16%, CMF +38%)

Broadening our Medical portfolio:
the growth of non-Spine revenues



Maintain and grow core applications

1

SPINE



ARTHROSCOPY



CMF



Develop non-Spine segments

2

CARDIO



DRUG DELIVERY



ACTIVE IMPLANTABLES



Invest to support game-changers

3

POROUS SPINE



TRAUMA



KNEE



MEDICAL GOALS:

1. DOUBLE MEDICAL REVENUES IN 5 YEARS
2. >30% OF GROUP REVENUES FROM MEDICAL BY 2032

MEGA-PROGRAMME UPDATE: TRAUMA

Invibio PEEK
composite Trauma
plate for foot &
ankle

DEMAND & CUSTOMER BASE GROWING


- Revenue closing on £1m; >3,000 Trauma plates supplied
- Potential £10m revenue opportunity in 2-3 years
- Strong customer feedback from In2Bones/CONMED
- Drive commercialisation from multiple customers



MEGA-PROGRAMME UPDATE: KNEE

FOCUSED ON COMMERCIALISATION ROADMAP

- Strong progress in Maxx clinical trial: 46 patient implants & 10 post two years (no intervention)
- Collaboration with top 5 Knee company, Aesculap (B Braun)
- Further customer interest: top 10 Knee companies
- Next milestone: US clinical trial in FY 2024
- Opportunity for first commercial PEEK Knee in 2-3 years




POTENTIAL FROM GAME-CHANGING MEGA-PROGRAMMES*

*mega-programmes offer at least £50m revenue pa in peak sales year

E-MOBILITY

- Current revenue £6m
- Additional business wins with wire coaters & OEMs
- Focus on 800V
- >200g PEEK content potential
- £10m revenue opportunity in <2 years



KNEE

- Clinical trial phase
- 46 patient implants, 10 post two years
- Top 5 OEM collaboration & growing interest
- Potential for a commercial PEEK Knee in 2025/26



MAGMA

- Current revenue >£1m
- Bid outcomes awaited (Brazil)
- c8 tonnes of PEEK/km of pipe
- TechnipFMC investing in new pipe facility



MOVING TO COMMERCIAL INFLECTION POINTS

TRAUMA

- Current revenue <£1m
- 4x demand via In2Bones contract
- Scale up of manufacturing
- Additional business wins, broader customer base
- £10m revenue opportunity in 2-3 years



AEROSPACE COMPOSITES

- Composite Parts & Structures
- Current revenue £3m
- Airbus, Boeing & other tiers
- >10x content opportunity
- Composite parts on planes (seat pans, brackets)
- Structural demonstrator parts progressing qualifications



INVESTMENT PRIORITISED IN 5 KEY PROGRAMMES TO ENHANCE STRATEGIC PROGRESS: PORTFOLIO VALUE UNCHANGED

ESG UPDATE:

Further progress in FY 2023



PEOPLE

Social responsibility



PLANET

Resource efficiency



PRODUCTS

Sustainable solutions



STEM PROGRAMME EXPANSION

Global programme with 58 STEM ambassadors including first in China

DECARBONISATION & SBTi ROADMAP

Targets submitted to SBTi across Scope 1,2 & 3 emissions
(aligned to Net Zero 2050 & 2032 interim target)

GROWTH IN SUSTAINABLE PRODUCT REVENUES

Sustainable product revenues at 55% (FY 2022: 48%)

WELL-PLACED FOR THE NEXT PHASE OF GROWTH

- China manufacturing
- UK asset upgrade
- Medical acceleration

- Volume growth & macro recovery
- Improved efficiency & returns
- Mega-programme contribution

- Volume step-up & expansion
- Mega-programme inflection
- Increase shareholder returns

INVESTMENT

DELIVERY

GROWTH & RETURNS

FY20-23

FY24-25

FY25+

NEW MID-TERM GROWTH TARGETS: MACRO-DRIVERS, DIFFERENTIATED PRODUCTS & MEGA-PROGRAMMES

GROUP CORE BUSINESS GROWTH

5-7% CAGR

(revenue 5-year period –
PBT ahead of revenue growth with
improving operating leverage)

GROWTH INC MEGA- PROGRAMMES

8-10% CAGR


(revenue 5-year period –
PBT ahead of revenue growth with
improving operating leverage)

MEGA-PROGRAMME PORTFOLIO

**c£25m-£35m of
Group revenues**
(in FY 2025)

MID-TERM CONFIDENCE UNDERPINS NEW STRATEGIC GROWTH TARGETS

DELIVERING THE UNTAPPED POTENTIAL OF PEEK



*Based on 800V long-term opportunity

**Statista forecast by 2030

SUMMARY & FY24 OUTLOOK

- **EXPECTING GOOD PROGRESS**
 - *GOOD REVENUE & PBT GROWTH*
 - *SUBJECT TO MACRO IMPROVEMENT (H2 FY 2024 WEIGHTED)*
- **POTENTIAL FOR DOUBLE-DIGIT GROWTH IN SALES VOLUME**
- **COGS/GM IMPACTED BY CHINA/LOWER ASSET UTILISATION**
- **LIMITED OPEX INCREASE**
- **WELL-PLACED FOR RECOVERY & GROWTH**

















APPENDIX

END-MARKET OUTLOOK

FY 2024*

	AEROSPACE	
	AUTOMOTIVE	
	MEDICAL	
	ELECTRONICS	
	ENERGY & INDUSTRIAL	
	VAR	

KEY


- OPTIMISTIC** 
- NEUTRAL** 
- CAUTIOUS** 

* Indicative outlook for our end-markets in FY 2024


GROUP END MARKETS

FY 2023: 3,598 tonnes (-24% vs FY 2022)
FY 2022: 4,727 tonnes (+8% vs FY 2021)

Volume by Region



Volume by Industry




* Medical volume reflects both non-implantable and implantable volumes.

MEDICAL: KEY MARKETS


FY 2023: £65.2m (+12% vs FY 2022)

FY 2022: £58.3m (+14% vs FY 2021)

Revenue by Region




Revenue by Market



MEGA-PROGRAMMES

The pathway to £10m revenue



KEY

- £0m-£1m phase
- £1m-£10m phase
- £10m+ phase

5 PRIORITISED MEGA-PROGRAMMES: POTENTIAL FOR EACH OF >£50m ANNUAL SALES IN PEAK YEAR

MEGA-PROGRAMME MILESTONES

PROGRAMME	REVENUE STATUS	FY 2023 MILESTONES	FY 2024 FOCUS
MAGMA	Commercial (£1m-£2m)	<ul style="list-style-type: none"> HFP bid process (TechnipFMC & Petrobras) Support for TFMC scale-up in Brazil 	<ul style="list-style-type: none"> Bid outcomes and scale up for 2025 commercialisation Qualification finalised
TRAUMA	Commercial <£1m	<ul style="list-style-type: none"> Demand 5x exceeded expectations Closing on £1m revenue & growing New manufacturing partner (Paragon) 	<ul style="list-style-type: none"> <u>Deliver meaningful revenue >£1m</u> Partnership and manufacturing scale up in Asia Broader customer portfolio (US & Asia)
E-MOBILITY	Commercial (£6m)	<ul style="list-style-type: none"> Major new business wins Strategic partnership (Well Ascent) 	<ul style="list-style-type: none"> <u>Commercialise additional applications</u> Further build commercial revenue closer to £10m
AERO COMPOSITES	Commercial (£3m)	<ul style="list-style-type: none"> Strong industry validation for AE™250 composite tape Extensive demonstrator parts 	<ul style="list-style-type: none"> Further qualifications Support positioning of thermoplastics in AAM Revenue build >£3m
KNEE	<£1m	<ul style="list-style-type: none"> 46 patient implants; clinical trial progress New 'top 5' player in Aesculap & further potential collaborations (top 10 companies) 	<ul style="list-style-type: none"> US clinical trial Pathway to commercial Knee in 2025/26

BUSINESS UNIT INCOME STATEMENTS

	2022				2023		
	Reported	Exc deals	Currency Spot Impact	Constant currency ¹	As reported	Exc Deals	Constant currency ¹
	£m	£m	£m	£m	£m	£m	£m
Industrial							
Revenue	282.7	282.7	8.1	290.8	241.8	241.8	-17%
Loss on foreign currency net hedging	(1.4)	-	-	-	(5.4)	-	
Gross profit	124.8	126.2	9.0	135.2	110.5	115.9	-14%
Gross margin %	44.1%	44.6%		46.5%	45.7%	47.9%	
Medical							
Revenue	58.3	58.3	2.4	60.7	65.2	65.2	7%
Loss on foreign currency net hedging	(1.4)	-	-	-	(2.2)	-	
Gross profit	49.7	51.1	2.3	53.4	52.1	54.3	2%
Gross margin %	85.3%	87.7%		88.0%	79.9%	83.3%	

¹ Alternative performance measures are defined in the Appendix on slide 38

BALANCE SHEET

	FY 2023	FY 2022
	£m	£m
PPE and intangible assets	369.9	367.4
Investment in associated undertakings	9.1	10.4
Financial assets held at fair value through profit and loss	13.2	10.1
Financial assets held at amortised cost	0.6	0.0
Retirement benefit asset (net)	7.2	12.2
Inventories	134.5	86.8
Trade receivables and other assets	49.2	68.1
Cash*	33.5	68.8
Current and deferred tax liabilities (net)	(30.1)	(21.5)
Borrowings**	(39.7)	(22.5)
Lease liabilities (IFRS 16)	(10.5)	(9.6)
Trade payables and other liabilities	(35.9)	(79.6)
Net assets	501.0	490.6
Share capital and share premium	62.8	62.4
Translation reserve	2.8	12.8
Hedging reserve	0.6	(13.6)
Retained earnings	432.8	427.2
Non Controlling Interest	2.0	1.8
Equity shareholders' funds	501.0	490.6

*Includes £3.4m (FY 2022: £2.8m) of cash ring-fenced in the Group's Chinese subsidiaries, and £0.1m (FY 2022: £10.1m) in 95-day deposit accounts

** Includes bank loan £31.6m (FY 2022: £15.7m) and loan payable to Non-controlling interest of £8.1m (FY 2022: £6.8m)

CAPITAL ALLOCATION

CAPEX

- Normalised capex c8-10% of sales
- Periodic capacity investment

M&A / INVESTMENT

- Investment to support mega-programmes
- Investment to enhance capability & IP

REGULAR DIVIDENDS

- Progressive dividend retained
- Maintain cover around c2x EPS over the cycle

SPECIAL DIVIDENDS

- Optionality to return cash if no additional investment opportunities
- 50p/share minimum

EXCESS CAPITAL DISTRIBUTION OPTIONS

SHARE BUYBACKS

- Existing approval to buyback 10% of shares
- Optionality for modest buybacks (c£20-£25m) to reflect share liquidity

PRIORITISE GROWTH INVESTMENT & RETAIN FLEXIBILITY
SHARE BUYBACKS NOW AN OPTION FOR SHAREHOLDER RETURN

DEFINITIONS

ALTERNATIVE PERFORMANCE MEASURES:

- 1) Constant currency metrics are reached by applying current year (FY 2023) weighted average spot rates to prior year (FY 2022) transactions. Gains and losses on foreign currency net hedging, are shown separately in the Income Statement and are excluded from the constant currency calculation;
- 2) Underlying PBT is profit before exceptional items and tax;
- 3) Operating cash conversion is operating cash flow / operating profit before exceptional items;
- 4) Operating cash flow is operating profit before exceptional items adjusted for depreciation, amortisation and loss on disposal, working capital and capital expenditure;
- 5) Free cash flow is net cash flow from operating activities adjusted for capital expenditure;
- 6) Available cash is cash and cash equivalents plus other financial assets (cash invested in deposit accounts greater than three months in duration) less cash ring-fenced in the Group's Chinese subsidiaries, which is not available to the wider Group;
- 7) Operating overheads is made up of sales, marketing and administrative expenses (including research and development expenditure) before exceptional items;
- 8) Underlying EPS is earnings per share based on profit after tax but before exceptional items divided by the weighted average number of shares in issue; and
- 9) FX hedge adjusted gross margin is gross profit / revenue + the impact of FX net hedging gains/losses. Including FX hedging within revenue, rather than as a standalone line item as required under IFRS 9, provides a more comparable gross margin over time and helps to show the main non-FX hedging related movements impacting it.

FORWARD LOOKING STATEMENTS

Forward-looking statements

Sections of this Presentation may contain forward-looking statements, including statements relating to: certain of the Group's plans and expectations relating to its future performance, results, strategic initiatives and objectives, future demand and markets for the Group's products and services; research and development relating to new products and services; and financial position, including its liquidity and capital resources.

These forward-looking statements are not guarantees of future performance. By their nature, all forward looking statements involve risks and uncertainties because they relate to events that may or may not occur in the future, and are or may be beyond the Group's control, including: changes in interest and exchange rates; changes in global, political, economic, business, competitive and market forces; changes in raw material pricing and availability; changes to legislation and tax rates; future business combinations or disposals; relations with customers and customer credit risk; events affecting international security, including global health issues and terrorism; the impact of, and changes in, legislation or the regulatory environment (including tax); and the outcome of litigation.

Accordingly, the Group's actual results and financial condition may differ materially from those expressed or implied in any forward-looking statements. Forward-looking statements in this Presentation are current only as of the date on which such statements are made. The Group undertakes no obligation to update any forward-looking statements, save in respect of any requirement under applicable law or regulation. Nothing in this Presentation shall be construed as a profit forecast.

#1 PEEK EXPERTS

First to commercialise PEEK, with unmatched knowledge and experience



INFORMATION & CONTACTS

Andrew Hanson

Director of IR,
Corporate Communications & ESG

+44 (0) 1253 898121
+44 (0) 7809 595831
ir@victrex.com
www.victrexplc.com

DRIVE CORE BUSINESS




Delivering the key PEEK & PAEK materials with No.1 manufacturing capacity of >8,000 tonnes (current nameplate capacity ex China)

DIFFERENTIATE THROUGH INNOVATION



POLYMER

Producing new grades including for Additive Manufacturing (3D Printing)



PRODUCT FORMS


Manufacturing product forms: Pipes, Films, Fibres and Composite Tapes

CREATE FUTURE VALUE



PARTS & COMPONENTS

Developing new applications for PEEK, PAEK and Thermoplastic Composites



UNDERPIN: SAFETY, SUSTAINABILITY, CAPABILITY

- Safety, health & wellbeing
- Sustainable business with sustainable products



GLOBAL CAPABILITY

c1000

Employees

40+

Countries served by Victrex across our markets

c£1.5bn

Market Value

- FTSE 250 Company
- >£300m Revenue



INVESTMENT IN INNOVATION

c5-6%

of annual sales invested in R&D

c£150m

Invested in manufacturing facilities in the last 5 years

NEW CAPABILITIES

- Partnerships
- Strategic Alliances
- Polymer Innovation Centre
- Acquisitions
- Composites Manufacturing
- Additive Manufacturing